BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11859424)

  • 1. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity.
    Steitz J; Brück J; Gambotto A; Knop J; Tüting T
    Gene Ther; 2002 Feb; 9(3):208-13. PubMed ID: 11859424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice.
    Brück J; Steitz J; Strand D; Tüting T
    J Gene Med; 2005 May; 7(5):613-20. PubMed ID: 15580620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity.
    Tüting T; Steitz J; Brück J; Gambotto A; Steinbrink K; DeLeo AB; Robbins P; Knop J; Enk AH
    J Gene Med; 1999; 1(6):400-6. PubMed ID: 10753065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism.
    Steitz J; Brück J; Knop J; Tüting T
    Gene Ther; 2001 Aug; 8(16):1255-63. PubMed ID: 11509959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2.
    Steitz J; Britten CM; Wölfel T; Tüting T
    Cancer Immunol Immunother; 2006 Mar; 55(3):246-53. PubMed ID: 16133114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
    Tan XH; Wan YH
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
    Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ
    Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination.
    Steitz J; Tormo D; Schweichel D; Tüting T
    Cancer Gene Ther; 2006 Mar; 13(3):318-25. PubMed ID: 16151477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice.
    Tüting T; Gambotto A; DeLeo A; Lotze MT; Robbins PD; Storkus WJ
    Cancer Gene Ther; 1999; 6(1):73-80. PubMed ID: 10078966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma.
    Shibagaki N; Udey MC
    Eur J Immunol; 2003 Apr; 33(4):850-60. PubMed ID: 12672050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune depigmentation following sensitization to melanoma antigens.
    Hurwitz AA; Ji Q
    Methods Mol Med; 2004; 102():421-7. PubMed ID: 15286398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
    Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
    Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Survival gene' Bcl-xl potentiates DNA-raised antitumor immunity.
    Kim JH; Chen J; Majumder N; Lin H; Falo LD; You Z
    Gene Ther; 2005 Oct; 12(20):1517-25. PubMed ID: 16052205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.
    Jia ZC; Zou LY; Ni B; Wan Y; Zhou W; Lv YB; Geng M; Wu YZ
    Cancer Immunol Immunother; 2005 May; 54(5):446-52. PubMed ID: 15750831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma.
    Steitz J; Brück J; Steinbrink K; Enk A; Knop J; Tüting T
    Int J Cancer; 2000 Apr; 86(1):89-94. PubMed ID: 10728600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
    Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
    Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.